Immune-related adverse events associated with mogamulizumab: A comprehensive review of the literature
Introduction Mogamulizumab is an anti-C–C chemokine receptor 4 antibody that is
increasingly being used to treat T-cell malignancies such as cutaneous T-cell lymphoma …
increasingly being used to treat T-cell malignancies such as cutaneous T-cell lymphoma …
Histopathological Markers for Target Therapies in Primary Cutaneous Lymphomas
B Sonego, A Ibatici, G Rivoli, E Angelucci, S Sola… - Cells, 2023 - mdpi.com
In recent years, targeted (biological) therapies have become available also for primary
cutaneous T-cell lymphomas (PCTCLs) including anti-CD30 (brentuximab vedotin) in …
cutaneous T-cell lymphomas (PCTCLs) including anti-CD30 (brentuximab vedotin) in …
Small-Molecule CCR4 Antagonists in Cutaneous T-cell Lymphoma
JS Enriquez, X Wang, LR Velatooru… - Cancer Research …, 2024 - aacrjournals.org
Mycosis fungoides (MF) and Sézary syndrome (SS) are two most common types of
cutaneous T-cell lymphoma (CTCL). Despite advances in understanding the pathogenesis …
cutaneous T-cell lymphoma (CTCL). Despite advances in understanding the pathogenesis …